Investigational Drug Information for fenebrutinib
✉ Email this page to a colleague
What is the development status for investigational drug fenebrutinib?
fenebrutinib is an investigational drug.
There have been 7 clinical trials for fenebrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 24th 2021.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Chronic Progressive. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and fifty-two international patents.
Summary for fenebrutinib
| US Patents | 8 |
| International Patents | 152 |
| US Patent Applications | 48 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2021-03-24) |
| Vendors | 37 |
Recent Clinical Trials for fenebrutinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 2 |
| Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
| A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
Clinical Trial Summary for fenebrutinib
Top disease conditions for fenebrutinib
Top clinical trial sponsors for fenebrutinib
US Patents for fenebrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| fenebrutinib | ⤷ Sign Up | Heteroaryl pyridone and aza-pyrodine compounds | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| fenebrutinib | ⤷ Sign Up | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| fenebrutinib | ⤷ Sign Up | Therapeutic compounds and compositions, and methods of use thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for fenebrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| fenebrutinib | Argentina | AR088641 | 2031-11-03 | ⤷ Sign Up |
| fenebrutinib | Argentina | AR117501 | 2031-11-03 | ⤷ Sign Up |
| fenebrutinib | Australia | AU2012332365 | 2031-11-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
